ArticlePathogens (Basel, Switzerland)2022
Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem-Nonsusceptible
Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Whole-Genome Sequencing Reveals Heterogeneous Resistance Profiles and Selected Mobile Genetic Elements in Ecuadorian ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Isolation and characterization of strictly lytic bacteriophages against carbapenem-resistantMicrobiology spectrum · 2025Article
- Molecular Epidemiology and Clinical Characterization of Carbapenemase-Producing Enterobacter Species From an International Cohort.The Journal of infectious diseases · 2025Observational
- Infections caused by clonal spread of metallo-beta-lactamase-producingMicrobiology spectrum · 2025Article
- Genomic analysis of Enterobacter cloacae complex from Southern Thailand reveals insights into multidrug resistance genotypes and genetic diversity.Scientific reports · 2025Article
- Clinical and microbiological analyses of colistin-resistant strains among carbapenem-resistantMicrobiology spectrum · 2025Article
- Presence and Role of the Type 3 Fimbria in the Adherence Capacity ofMicroorganisms · 2024Article
- Therapeutic Potential of a Novel Lytic Phage, vB_EclM_ECLFM1, against Carbapenem-ResistantInternational journal of molecular sciences · 2024Article
- Economic and health impact modelling of a whole genome sequencing-led intervention strategy for bacterial healthcare-associated infections for England and for the USA.Microbial genomics · 2023Article
- The Resistance Mechanisms and Clinical Impact of Resistance to the Third Generation Cephalosporins in Species ofAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.